GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (STU:2TZ) » Definitions » ROC (Joel Greenblatt) %

Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) ROC (Joel Greenblatt) % : 30.45% (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Tianjin Pharmaceutical Da Ren Tang Group ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Tianjin Pharmaceutical Da Ren Tang Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 30.45%.

The historical rank and industry rank for Tianjin Pharmaceutical Da Ren Tang Group's ROC (Joel Greenblatt) % or its related term are showing as below:

STU:2TZ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 24.47   Med: 30.62   Max: 54.29
Current: 43.76

During the past 13 years, Tianjin Pharmaceutical Da Ren Tang Group's highest ROC (Joel Greenblatt) % was 54.29%. The lowest was 24.47%. And the median was 30.62%.

STU:2TZ's ROC (Joel Greenblatt) % is ranked better than
83.55% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 9.36 vs STU:2TZ: 43.76

Tianjin Pharmaceutical Da Ren Tang Group's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 12.50% per year.


Tianjin Pharmaceutical Da Ren Tang Group ROC (Joel Greenblatt) % Historical Data

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Pharmaceutical Da Ren Tang Group ROC (Joel Greenblatt) % Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.37 31.64 35.46 41.40 52.94

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.85 21.93 77.35 65.86 30.45

Competitive Comparison of Tianjin Pharmaceutical Da Ren Tang Group's ROC (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianjin Pharmaceutical Da Ren Tang Group's ROC (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianjin Pharmaceutical Da Ren Tang Group's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Tianjin Pharmaceutical Da Ren Tang Group's ROC (Joel Greenblatt) % falls into.



Tianjin Pharmaceutical Da Ren Tang Group ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(332.686 + 199.122 + 21.981) - (545.238 + 0 + 20.97)
=-12.419

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(302.072 + 207.642 + 143.524) - (389.142 + 0 + 8.973)
=255.123

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Tianjin Pharmaceutical Da Ren Tang Group for the quarter that ended in Sep. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=95.5/( ( (187.134 + max(-12.419, 0)) + (185.078 + max(255.123, 0)) )/ 2 )
=95.5/( ( 187.134 + 440.201 )/ 2 )
=95.5/313.6675
=30.45 %

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tianjin Pharmaceutical Da Ren Tang Group  (STU:2TZ) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Tianjin Pharmaceutical Da Ren Tang Group ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Tianjin Pharmaceutical Da Ren Tang Group's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin Pharmaceutical Da Ren Tang Group Business Description

Traded in Other Exchanges
Address
No. 17 Baidi Road, Zhong Xin Mansion, Nankai District, Tianjin, CHN, 300193
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.

Tianjin Pharmaceutical Da Ren Tang Group Headlines

No Headlines